Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session.
Inclisiran, the first cholesterol-lowering therapy in the siRNA class, has the potential to deliver consistent lowering of LDL cholesterol through twice-a-year dosing.
Among the results presented today:
MIAMI, Fla. – (May 18, 2019) -- Clinical lipidology’s best and brightest up-and-comers have been singled out for their exceptional abstracts at the National Lipid Association’s (NLA) 2019 Scientific Sessions, taking place May 16 – 19 in Miami.
Five Young Investigator Abstract Award Winners were selected from those engaged in innovative research work in the field of clinical lipidology and cardiovascular disease prevention. The competition is open to in-training students, residents, fellows and NLA members in practice for five years or less.
MIAMI, Fla. – (May 18, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions.
.jpg)
.png)
(1).png)
